Abeona Therapeutics (ABEO) Announces Proposed Common Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Abeona Therapeutics (ABEO) Granted EMA PRIME Designation for ABO-102 Gene Therapy in MPS IIIA
December 20, 2019 8:27 AM ESTAbeona Therapeutics Inc. (NASDAQ: ABEO) today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to the Companys ABO-102 program studying its adeno-associated virus 9 (AAV9) gene therapy for Sanfilippo syndrome type A (MPS IIIA). The PRIME designation is based on nonclinical data and clinical data from the Transpher A Study, a global Phase 1/2 clinical trial evaluating a single-dose of ABO-102 for the treatment of children with MPS IIIA.
EMAs PRIME designation for the ABO-102 program recognizes the urgent need for a treatment option for children... More
